Cormedix Stock News

CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix Inc. (CRMD) CEO Matt David on Q4 2021 Results - Earnings Call Transcript

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug Pfizer, Inc.

BERKELEY HEIGHTS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention

Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a

Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and specialty pharmaceuticals industry Joseph Todi

Gainers Marygold Companies (NYSE: MGLD ) jumped 189.4% to $6.28 after dropping 21% on Thursday. Altamira Therapeutics Ltd. (NASDAQ: CYTO ) shares rose 63.5% to $1.13. Altamira Therapeutics reported in vitro efficacy data for bentrio nasal spray in protecting against Sars-CoV-2 omicron variant. Excellon Resources Inc. (NYSE: EXN ) rose 40.7% to $1.38 after jumping around 13% on Thursday. Clearside Biomedical, Inc. (NASDAQ: CLSD ) rose 35.5% to $1.8301 after the company reported better-than-expected Q4 results. Alset EHome International Inc. (NASDAQ: AEI ) shares rose 31% to $ 0.4555 after dropping 7% on Thursday. Humanigen, Inc. (NASDAQ: HGEN ) jumped 22.7% to $3.44. Lazydays Holdings, Inc. (NASDAQ: LAZY ) gained 22% to $21.80 after the company reported Q4 earnings results. Blue Star Foods Corp. (NASDAQ: BSFC ) jumped 19.8% to $2.54. 4D pharma plc (NASDAQ: LBPS ) shares climbed 19.7% to $3.53. Paramount Gold Nevada Corp. (NYSE: PZG ) rose 19% to $0.9404 after jumping 14% on Thursday. Pearson plc (NYSE: PSO ) gained 19% to $10.35.

Puma Biotech (PBYI) delivered earnings and revenue surprises of 190.91% and 16.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -20.29% and 14.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc